Hervycta 440mg Trastuzumab Injection

Hervycta 440mg Trastuzumab Injection is a prescription targeted anti-cancer medication used in the treatment of HER2-positive breast cancer and HER2-positive gastric cancer. It contains Trastuzumab, a monoclonal antibody that specifically targets the HER2 (human epidermal growth factor receptor 2) protein found on certain cancer cells. By blocking HER2 signaling pathways, Hervycta 440mg Trastuzumab Injection helps slow the growth and spread of cancer cells, supporting improved treatment outcomes and long-term disease management. Administered as an intravenous infusion under the supervision of an oncology specialist, it may be used alone or in combination with chemotherapy and other targeted therapies. Regular monitoring of heart function and overall health is essential during treatment to ensure safety and effectiveness. Patients should use Hervycta 440mg Trastuzumab Injection only as prescribed by their healthcare provider.